vs

Side-by-side financial comparison of Ecovyst Inc. (ECVT) and VERACYTE, INC. (VCYT). Click either name above to swap in a different company.

Ecovyst Inc. is the larger business by last-quarter revenue ($199.4M vs $140.6M, roughly 1.4× VERACYTE, INC.). On growth, Ecovyst Inc. posted the faster year-over-year revenue change (34.0% vs 18.5%). VERACYTE, INC. produced more free cash flow last quarter ($48.8M vs $22.9M). Over the past eight quarters, VERACYTE, INC.'s revenue compounded faster (20.5% CAGR vs 18.7%).

Ecovyst Inc. is a global sustainable specialty materials provider that develops and manufactures high-performance catalysts and functional additives. Its offerings serve key segments including industrial manufacturing, consumer goods, and environmental protection, helping clients improve operational efficiency and lower carbon emissions across North America, Europe, and Asia-Pacific markets.

Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.

ECVT vs VCYT — Head-to-Head

Bigger by revenue
ECVT
ECVT
1.4× larger
ECVT
$199.4M
$140.6M
VCYT
Growing faster (revenue YoY)
ECVT
ECVT
+15.4% gap
ECVT
34.0%
18.5%
VCYT
More free cash flow
VCYT
VCYT
$25.9M more FCF
VCYT
$48.8M
$22.9M
ECVT
Faster 2-yr revenue CAGR
VCYT
VCYT
Annualised
VCYT
20.5%
18.7%
ECVT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ECVT
ECVT
VCYT
VCYT
Revenue
$199.4M
$140.6M
Net Profit
$41.1M
Gross Margin
23.4%
72.5%
Operating Margin
10.9%
26.4%
Net Margin
29.3%
Revenue YoY
34.0%
18.5%
Net Profit YoY
704.8%
EPS (diluted)
$0.06
$0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ECVT
ECVT
VCYT
VCYT
Q4 25
$199.4M
$140.6M
Q3 25
$204.9M
$131.9M
Q2 25
$176.1M
$130.2M
Q1 25
$143.1M
$114.5M
Q4 24
$148.9M
$118.6M
Q3 24
$153.9M
$115.9M
Q2 24
$154.0M
$114.4M
Q1 24
$141.6M
$96.8M
Net Profit
ECVT
ECVT
VCYT
VCYT
Q4 25
$41.1M
Q3 25
$-79.3M
$19.1M
Q2 25
$6.0M
$-980.0K
Q1 25
$-3.6M
$7.0M
Q4 24
$5.1M
Q3 24
$14.3M
$15.2M
Q2 24
$8.3M
$5.7M
Q1 24
$1.2M
$-1.9M
Gross Margin
ECVT
ECVT
VCYT
VCYT
Q4 25
23.4%
72.5%
Q3 25
25.4%
69.2%
Q2 25
22.8%
69.0%
Q1 25
13.3%
69.5%
Q4 24
28.9%
66.4%
Q3 24
29.3%
68.2%
Q2 24
27.3%
68.1%
Q1 24
23.5%
64.5%
Operating Margin
ECVT
ECVT
VCYT
VCYT
Q4 25
10.9%
26.4%
Q3 25
13.8%
17.4%
Q2 25
9.0%
-4.0%
Q1 25
-0.7%
2.5%
Q4 24
15.1%
3.5%
Q3 24
17.9%
10.4%
Q2 24
14.1%
4.0%
Q1 24
9.5%
-4.8%
Net Margin
ECVT
ECVT
VCYT
VCYT
Q4 25
29.3%
Q3 25
-38.7%
14.5%
Q2 25
3.4%
-0.8%
Q1 25
-2.5%
6.2%
Q4 24
4.3%
Q3 24
9.3%
13.1%
Q2 24
5.4%
5.0%
Q1 24
0.9%
-1.9%
EPS (diluted)
ECVT
ECVT
VCYT
VCYT
Q4 25
$0.06
$0.50
Q3 25
$-0.69
$0.24
Q2 25
$0.05
$-0.01
Q1 25
$-0.03
$0.09
Q4 24
$-0.26
$0.07
Q3 24
$0.12
$0.19
Q2 24
$0.07
$0.07
Q1 24
$0.01
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ECVT
ECVT
VCYT
VCYT
Cash + ST InvestmentsLiquidity on hand
$197.2M
$362.6M
Total DebtLower is stronger
$392.6M
Stockholders' EquityBook value
$603.4M
$1.3B
Total Assets
$1.3B
$1.4B
Debt / EquityLower = less leverage
0.65×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ECVT
ECVT
VCYT
VCYT
Q4 25
$197.2M
$362.6M
Q3 25
$82.0M
$315.6M
Q2 25
$69.6M
$219.5M
Q1 25
$127.5M
$186.1M
Q4 24
$131.4M
$239.1M
Q3 24
$123.5M
$274.1M
Q2 24
$83.3M
$235.9M
Q1 24
$103.1M
$209.2M
Total Debt
ECVT
ECVT
VCYT
VCYT
Q4 25
$392.6M
Q3 25
$854.8M
Q2 25
$856.6M
Q1 25
$859.0M
Q4 24
$860.8M
Q3 24
$862.7M
Q2 24
$862.4M
Q1 24
$866.2M
Stockholders' Equity
ECVT
ECVT
VCYT
VCYT
Q4 25
$603.4M
$1.3B
Q3 25
$607.9M
$1.3B
Q2 25
$692.4M
$1.2B
Q1 25
$698.7M
$1.2B
Q4 24
$700.5M
$1.2B
Q3 24
$729.4M
$1.2B
Q2 24
$717.3M
$1.1B
Q1 24
$711.4M
$1.1B
Total Assets
ECVT
ECVT
VCYT
VCYT
Q4 25
$1.3B
$1.4B
Q3 25
$1.7B
$1.4B
Q2 25
$1.8B
$1.3B
Q1 25
$1.8B
$1.3B
Q4 24
$1.8B
$1.3B
Q3 24
$1.8B
$1.3B
Q2 24
$1.8B
$1.2B
Q1 24
$1.8B
$1.2B
Debt / Equity
ECVT
ECVT
VCYT
VCYT
Q4 25
0.65×
Q3 25
1.41×
Q2 25
1.24×
Q1 25
1.23×
Q4 24
1.23×
Q3 24
1.18×
Q2 24
1.20×
Q1 24
1.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ECVT
ECVT
VCYT
VCYT
Operating Cash FlowLast quarter
$41.8M
$52.6M
Free Cash FlowOCF − Capex
$22.9M
$48.8M
FCF MarginFCF / Revenue
11.5%
34.7%
Capex IntensityCapex / Revenue
9.4%
2.7%
Cash ConversionOCF / Net Profit
1.28×
TTM Free Cash FlowTrailing 4 quarters
$69.9M
$126.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ECVT
ECVT
VCYT
VCYT
Q4 25
$41.8M
$52.6M
Q3 25
$55.3M
$44.8M
Q2 25
$33.0M
$33.6M
Q1 25
$10.3M
$5.4M
Q4 24
$43.5M
$24.5M
Q3 24
$59.9M
$30.0M
Q2 24
$10.0M
$29.6M
Q1 24
$36.5M
$-9.0M
Free Cash Flow
ECVT
ECVT
VCYT
VCYT
Q4 25
$22.9M
$48.8M
Q3 25
$53.2M
$42.0M
Q2 25
$7.8M
$32.3M
Q1 25
$-14.0M
$3.5M
Q4 24
$30.9M
$20.4M
Q3 24
$53.6M
$27.7M
Q2 24
$-9.3M
$26.8M
Q1 24
$19.1M
$-11.1M
FCF Margin
ECVT
ECVT
VCYT
VCYT
Q4 25
11.5%
34.7%
Q3 25
26.0%
31.8%
Q2 25
4.4%
24.8%
Q1 25
-9.8%
3.1%
Q4 24
20.7%
17.2%
Q3 24
34.9%
23.9%
Q2 24
-6.1%
23.4%
Q1 24
13.5%
-11.5%
Capex Intensity
ECVT
ECVT
VCYT
VCYT
Q4 25
9.4%
2.7%
Q3 25
1.0%
2.1%
Q2 25
14.4%
1.0%
Q1 25
16.9%
1.6%
Q4 24
8.5%
3.5%
Q3 24
4.1%
1.9%
Q2 24
12.5%
2.4%
Q1 24
12.3%
2.2%
Cash Conversion
ECVT
ECVT
VCYT
VCYT
Q4 25
1.28×
Q3 25
2.34×
Q2 25
5.52×
Q1 25
0.76×
Q4 24
4.80×
Q3 24
4.21×
1.98×
Q2 24
1.20×
5.16×
Q1 24
29.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ECVT
ECVT

Industrial Mining Automotive$101.3M51%
Regeneration And Treatment Services$90.0M45%
Other$8.1M4%

VCYT
VCYT

Testing$135.8M97%
Products$3.8M3%
Biopharmaceutical And Other$686.0K0%

Related Comparisons